Abstract:Background: The ability to generate functional hepatocytes without relying on donor liver organs holds significant therapeutic promise in the fields of regenerative medicine and potential liver disease treatments. Clustered regularly interspaced short palindromic repeats (CRISPR) activator (CRISPRa) is a powerful tool that can conveniently and efficiently activate the expression of multiple endogenous genes simultaneously, providing a new strategy for cell fate determination. The main purpose of this study is to explore the feasibility of applying CRISPRa for hepatocyte reprogramming and its application in the treatment of mouse liver fibrosis. Method: The differentiation of mouse embryonic fibroblasts (MEFs) into functional induced hepatocyte-like cells (iHeps) was achieved by utilizing the CRISPRa synergistic activation mediator (SAM) system, which drove the combined expression of three endogenous transcription factors—Gata4, Foxa3, and Hnf1a—or alternatively, the expression of two transcription factors, Gata4 and Foxa3. In vivo, we injected adeno-associated virus serotype 6 (AAV6) carrying the CRISPRa SAM system into liver fibrotic Col1a1-CreER; Cas9fl/fl mice, effectively activating the expression of endogenous Gata4 and Foxa3 in fibroblasts. The endogenous transcriptional activation of genes was confirmed using real-time quantitative polymerase chain reaction (RT-qPCR) and RNA-seq, and the morphology and characteristics of the induced hepatocytes were observed through microscopy. The level of hepatocyte reprogramming in vivo is detected by immunofluorescence staining, while the improvement of liver fibrosis is evaluated through Sirius red staining, alpha-smooth muscle actin (α-SMA) immunofluorescence staining, and blood alanine aminotransferase (ALT) examination. Results: Activation of only two factors, Gata4 and Foxa3, via CRISPRa was sufficient to successfully induce the transformation of MEFs into iHeps. These iHeps could be expanded in vitro and displayed functional characteristics similar to those of mature hepatocytes, such as drug metabolism and glycogen storage. Additionally, AAV6-based delivery of the CRISPRa SAM system effectively induced the hepatic reprogramming from fibroblasts in mice with live fibrosis. After 8 weeks of induction, the reprogrammed hepatocytes comprised 0.87% of the total hepatocyte population in the mice, significantly reducing liver fibrosis. Conclusion: CRISPRa-induced hepatocyte reprogramming may be a promising strategy for generating functional hepatocytes and treating liver fibrosis caused by hepatic diseases.

CRISPR/dCas9-mediated Activation of Multiple Endogenous Target Genes Directly Reprograms Human Foreskin Fibroblasts into Leydig-like Cells

Epigenome editing based on CRISPR/dCas9p300 facilitates transdifferentiation of human fibroblasts into Leydig-like cells

High-fidelity Reprogramming into Leydig-like Cells by CRISPR Activation and Paracrine Factors.

Leydig-like Cells Derived from Reprogrammed Human Foreskin Fibroblasts by CRISPR/dCas9 Increase the Level of Serum Testosterone in Castrated Male Rats

Direct Conversion of Human Fibroblasts into Functional Leydig-like Cells by SF-1, GATA4 and NGFI-B.

Conversion of Human Fibroblasts into Functional Leydig-like Cells by Small Molecules and a Single Factor.

Direct Reprogramming of Mouse Fibroblasts Toward Leydig-like Cells by Defined Factors

Conversion of Fibroblast into Functional Leydig-like Cell Using Defined Small Molecules

Differentiation of human induced pluripotent stem cells into Leydig-like cells with molecular compounds

Generation of Leydig-like Cells: Approaches, Characterization, and Challenges

Directed Mouse Embryonic Stem Cells into Leydig-Like Cells Rescue Testosterone-Deficient Male Rats in Vivo.

Direct reprogramming of fibroblasts into functional hepatocytes via CRISPRa activation of endogenous Gata4 and Foxa3

Directing differentiation of human induced pluripotent stem cells toward androgen-producing Leydig cells rather than adrenal cells

Pharmacological Reprogramming of Fibroblasts into Neural Stem Cells by Signaling-Directed Transcriptional Activation

Direct Cardiac Reprogramming Via Combined CRISPRa-Mediated Endogenous Gata4 Activation and Exogenous Mef2c and Tbx5 Expression

Characterization of Nestin-positive stem Leydig cells as a potential source for the treatment of testicular Leydig cell dysfunction

NGF Induces Adult Stem Leydig Cells to Proliferate and Differentiate During Leydig Cell Regeneration

Differentiation of umbilical cord mesenchymal stem cells into Leydig cells using a new lentiviral vector

Induced Differentiation of Human Adipose-Derived Stem Cells into Leydig Cells in Vitro

Transplanted Human P75-Positive Stem Leydig Cells Replace Disrupted Leydig Cells for Testosterone Production

Proliferated Leydig cells for engineered testis-like tissue regeneration with testosterone-secreting ability